PNPLA3 rs738409 G allele carriers with genotype 1b HCV cirrhosis have lower viral load but develop liver failure at younger age

Renata Senkerikova¹,², Sona Frankova¹, Milan Jirsa²,³, Miluse Kreidlova⁴, Dusan Merta⁵, Magdalena Neroldova²,³, Klara Chmelova¹,², Julius Spicak¹, Jan Sperl¹,²*¹

¹ Department of Hepatogastroenterology, Transplant Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, ² Charles University, First Faculty of Medicine, Prague, Czech Republic, ³ Laboratory of Experimental Hepatology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, ⁴ Institute of Medical Biochemistry and Laboratory Diagnostics First Faculty of Medicine Charles University and General University Hospital in Prague, Prague, Czech Republic, ⁵ Anesthesiology, Resuscitation and Intensive Care Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

* jan.sperl@ikem.cz

Abstract

Background

PNPLA3 rs738409 minor allele c.444G represents a risk factor for liver steatosis and fibrosis progression also in chronic hepatitis C (HCV). We investigated its impact on the timing of liver transplantation (LT) in patients with genotype 1b HCV cirrhosis.

Methods

We genotyped and evaluated 172 LT candidates with liver cirrhosis owing to chronic HCV infection, genotype 1b. One hundred patients needed LT for chronic liver failure (CLF) and 72 for a small hepatocellular carcinoma (HCC) in the cirrhotic liver without CLF. Population controls (n = 647) were selected from the Czech cross-sectional study MONICA.

Results

The CLF patients were younger (53.5 ± 7.2 vs. 59.6 ± 6.6, P < 0.001) with more advanced liver disease than HCC patients (Child-Pugh’s score 9.1 ± 1.8 vs. 7.1 ± 1.9, P < 0.001, MELD 14.1 ± 3.9 vs. 11.1 ± 3.7, P < 0.001). PNPLA3 G allele increased the risk of LT for CLF in both allelic and recessive models (CG + GG vs. CC: OR, 1.90; 95% CI, 1.017–3.472, P = 0.045 and GG vs. CC + CG: OR, 2.94; 95% CI, 1.032–7.513, P = 0.042). Multivariate analysis identified younger age (P < 0.001) and the G allele (P < 0.05) as risk factors for CLF. The genotype frequencies between the CLF group and MONICA study significantly differed in both, allelic and recessive model (P = 0.004, OR 1.87, 95% CI 1.222–2.875; P < 0.001, OR 3.33, 95% CI 1.824–6.084, respectively). The OR values almost doubled in the recessive model compared with the allelic model suggesting the additive effect of allele G. In contrast, genotype frequencies in the HCC group were similar to the MONICA study in both models.
Pretransplant viral load was significantly lower in GG than in CC + CG genotypes (median, IQR; 162,500 (61,550–319,000) IU/ml vs. 570,000 (172,000–1,595,000) IU/ml, \( P < 0.0009 \)).

Conclusions
Our results suggest that PNPLA3 rs738409 G allele carriage may be associated with a faster progression of HCV cirrhosis to chronic liver failure.

Introduction
Adequate timing of liver transplantation (LT) represents one of the main factors determining favourable posttransplant outcome. Prediction of the patients’ prognosis based on the known natural course of a particular liver disease is crucial in the evaluation process [1]. The natural course of liver diseases may be altered by genetic factors. Single nucleotide polymorphism rs738409 c.444C>G (p.Ile148Met) in the patatin-like phospholipase domain-containing protein 3 (PNPLA3) is nowadays one of the most important genetic factors with an impact on progression of several liver diseases of different etiology [2].

Association between liver fat content as a quantitative trait and PNPLA3 rs738409 genotype was described in a large genome-wide association mapping study [3] in 2008 and confirmed in a more detailed study [4] by the same group of authors in 2014. More than fifty studies demonstrating that the PNPLA3 rs738409 G allele is a risk factor for non-alcoholic steatohepatitis (NASH), liver cirrhosis in NASH or alcoholic liver disease have been published in the past decade [5–11]. The same allele was also identified as a risk factor for liver fibrosis and cirrhosis in HCV-monoinfected individuals [12–16] and in those with HCV/HIV coinfection [17–20] and it also turned out to be a predisposing factor of hepatocellular carcinoma (HCC) [21–24].

In a recent study, the increased risk of HCC and PNPLA3 G allele was found only in alcoholic liver disease, but not in non-alcoholic fatty liver disease or viral hepatitis B and C [25].

Whereas the impact of the G allele on the liver fibrosis progression in chronic hepatitis C seems to be well known, its impact on chronic liver failure (CLF) progression and the need of LT has not been described so far. In this study, we aimed to investigate the impact of PNPLA3 genotypes on the risk of CLF in a homogenous group of cirrhotic patients infected with HCV genotype 1b.

Patients and methods
Study design and eligibility of patients
We retrospectively evaluated 172 adult patients with HCV-related cirrhosis caused by HCV genotype 1b with Child-Pugh’s class A, B and C who underwent LT between January 1995 and August 2018 at our center. One hundred patients were enlisted for LT and transplanted for CLF (CLF group) using standard criteria evaluating liver dysfunction according to the Child-Pugh’s and MELD score and 72 patients were transplanted for a small HCC (HCC group). Fifty-two patients fulfilled Milan criteria, remaining 20 complied with San Francisco or up-to-seven criteria based on pre-transplant imaging techniques results [26–28]. The diagnosis of HCC was confirmed in the liver explants using standard histological staining techniques. Neither patients with HBsAg positivity nor those with HbcAb positivity were included. Patients combining HCV infection with excessive alcohol consumption (60 g per day in males and 40 g per day in females) were also excluded. None of HCV-infected patients had obtained antiviral...
treatment in the year preceding LT in accordance with our centre anti-HCV treatment policy: very short times in the liver transplant waiting list, 80–90 days, do not allow for a safe entire treatment course before LT, even in the era of direct acting antivirals. The patients were treated after LT according to the period of transplantation, using an interferon-based regimen until 2014 or a direct acting antivirals combination thereafter. Demographic, clinical, laboratory and histological data were collected from the internal hospital and outpatient database (S1 Table).

Genotype frequencies in both CLF and HCC groups were compared with the PNPLA3 genotype frequencies in 647 subjects 0.566/0.372/0.062 (CC/CG/GG) reported in the Czech cross-sectional population study MONICA [29], genotyping data were taken from Trunecka et al. [30].

HCV viral load and HCV genotype assessment
HCV viral loads (serum HCV RNA levels) were determined in blood samples taken from HCV-infected patients within 24 hours before LT (last value unaffected by immunosuppression or antiviral therapy). In 133 patients, serum HCV RNA level was assessed according to the period of sampling by the Roche COBAS® AmpliPrep/COBAS® TaqMan® HCV Quantitative Test v1.0 or v2.0 (Roche Molecular Systems Inc., South Branchburg, NJ).

In the 39 remaining patients, only an in-house quantitative method was used and therefore those results were not included in the statistical analysis. HCV genotype was assessed using the SIEMENS Versant® HCV Genotype 2.0 Assay (LiPA) (Siemens Healthcare Diagnostics Inc., Tarrytown, NY).

Genotyping
DNA was isolated from the peripheral blood using the Qiagen QIAamp kit (Qiagen, Hilden, Germany). All patients were genotyped for the PNPLA3 rs738409 c.444C>G polymorphism by the TaqMan predesigned SNP genotyping assay No. C_7241_10 (Thermo Fisher Scientific, Waltham, MA). Genotyping was performed according to the manufacturer’s protocol using the Applied Biosystems ABI 7300 Real-Time PCR instrument (Thermo Fischer Scientific). No significant deviation from the Hardy-Weinberg equilibrium was observed in PNPLA3 genotypes distribution within the CLF and HCC patient groups.

Statistical analysis
Continuous variables are presented as means and standard deviations, whereas categorical variables are expressed as frequencies (%). Categorical data were analyzed using the chi-square test. For continuous data, Student’s t-test or the non-parametric Mann-Whitney test were used appropriately. Genotype frequencies were determined and tested for consistency with the Hardy-Weinberg equilibrium using the chi-square test. Testing for genetic associations was performed as described in [31]. Risk factors were examined using multivariate logistic regression analysis. All statistical analyses were two-sided and P value of < 0.05 was considered statistically significant throughout the study. Statistical analysis was performed using the R programming language version 3.2.0 (www.r-project.org).

Ethics statement
This study was approved by the Ethics Committee of the Thomayer Hospital and Institute for Clinical and Experimental Medicine, Prague, Czech Republic, and was carried out in compliance with the Helsinki Declaration. The patients’ informed consent was not required by local
law because of the retrospective design of the study and the use of data from which the patients’ identification information had been removed. All study participants gave written consent to the storage of blood samples and agreed to using blood for future research including genetic testing. The written consent was obtained before enlistment for LT.

Results

Demographic, clinical data and laboratory data

Demographic, clinical and laboratory data of the CLF and HCC groups are shown in Table 1. Patients transplanted for CLF were younger with a higher proportion of males and suffered from more advanced liver disease according to the Child-Pugh’s and MELD score in comparison with the HCC group. Patients in CLF group had lower AFP levels and lower total cholesterol, HDL and serum triglycerides levels.

Pretransplant viral load

Pretransplant viral load was known in 133 of 172 HCV cirrhotic patients. HCV patients with known pretransplant viral load included 66 of 82 patients with the PNPLA3 rs738409

Table 1. Demographic, clinical and laboratory data of subgroups with CLF and HCC.

| Variables                  | CLF group n = 100 | HCC group n = 72 | P value |
|----------------------------|-------------------|------------------|---------|
| Males (n)                  | 68 (68.0%)        | 38 (52.8%)       | 0.0428  |
| Age (years)                | 53.5 ± 7.2        | 59.6 ± 6.6       | < 0.001 |
| BMI (kg/m²)                | 26.2 ± 4.2        | 26.8 ± 3.7       | 0.175   |
| Type 2 diabetes mellitus   |                   |                  |         |
| A                          | 6 (6.0)           | 37 (51.4)        | < 0.001 |
| B                          | 48 (48.0)         | 27 (37.5)        |         |
| C                          | 46 (46.0)         | 8 (11.1)         |         |
| Child-Pugh’s class         |                   |                  |         |
| A                          | 6 (6.0)           | 37 (51.4)        | < 0.001 |
| B                          | 48 (48.0)         | 27 (37.5)        |         |
| C                          | 46 (46.0)         | 8 (11.1)         |         |
| Child-Pugh’s score (points)| 9.1 ± 1.8         | 7.1 ± 1.9        | < 0.001 |
| MELD score (points)        | 14.1 ± 3.9        | 11.1 ± 3.7       | < 0.001 |
| Ascites                    |                   |                  | < 0.001 |
| None                       | 44 (44.0)         | 53 (73.6)        |         |
| Small                      | 32 (32.0)         | 14 (19.5)        |         |
| Large                      | 24 (24.0)         | 5 (6.9)          |         |
| AFP (μg/l)                 | 34.5 ± 50.1       | 337.1 ± 926.8    | < 0.001 |
| Total bilirubin (μmol/l)   | 51.8 ± 77.3       | 35.6 ± 46.7      | < 0.001 |
| Albumin (g/l)              | 29.0 ± 6.5        | 33.5 ± 6.8       | < 0.001 |
| ALT (μkat/l)               | 1.3 ± 0.9         | 1.5 ± 1.2        | 0.117   |
| Total cholesterol (mmol/l) | 3.4 ± 1.0         | 3.7 ± 1.0        | 0.004   |
| HDL cholesterol (mmol/l)   | 0.9 ± 0.4         | 1.1 ± 0.4        | 0.037   |
| LDL cholesterol (mmol/l)   | 1.9 ± 0.8         | 2.1 ± 0.7        | 0.080   |
| Triglycerides (mmol/l)     | 1.1 ± 0.5         | 1.3 ± 0.7        | 0.009   |
| Prothrombin time (INR)     | 1.4 ± 0.3         | 1.2 ± 0.2        | < 0.001 |

Data are given as number, number (%), or mean ± SD.

Abbreviations: CLF, chronic liver failure; HCC, hepatocellular carcinoma; BMI, body mass index; MELD, Model for End-Stage Liver Disease; AFP, alpha-fetoprotein; ALT, alanine-aminotransferase; HDL, cholesterol, high density lipoprotein cholesterol; LDL, cholesterol, low density lipoprotein cholesterol; INR, International normalized ratio.

https://doi.org/10.1371/journal.pone.0222609.t001
CC genotype, 51 of 67 patients with the CG genotype and 16 of 23 patients with the GG genotype.

Similarly, pretransplant viral load was available in 68 of 100 patients with CLF and in 65 of 72 patients with HCC. PNPLA3 GG homozygotes had a significantly lower pretransplant HCV viral load in comparison with the C allele carriers (median, interquartile range [IQR]; GG 162,500 (61,550–319,000) IU/ml vs. CC+CG 570,000 (172,000–1,595,000) IU/ml, \( P < 0.001 \), Fig 1A). Pre-transplant viral load was significantly lower in patients with CLF in comparison with patients with HCC (median [IQR]; CLF 292,500 (83,725–829,801) IU/ml vs. HCC 806,000 (237,000–1,680,000), \( P = 0.008 \)).

PNPLA3 rs738409 genotype association with CLF

PNPLA3 genotype frequency differences between the CLF and HCC groups were found in both allelic and recessive models (Table 2A) (\( p < 0.05 \)). Genotype frequencies between the CLF group and Czech cross-sectional population study MONICA significantly differed with \( P = 0.004 \) for the allelic model (OR 1.87, 95% CI 1.22–2.87, test power with \( \alpha = 0.05 \): 0.85) and \( P < 0.001 \) for the recessive model (OR 3.33, 95% CI 1.82–6.08 (Table 2B). The OR values almost doubled in the recessive model compared with the allelic model indicating the additive effect of allele G (Fig 1B). By contrast, genotype frequencies in the HCC group were the same as in the MONICA study in both models (Table 2C). Importantly, the minor allele frequency in the MONICA study (0.25) did not differ from the frequencies recorded in European population subsets of the GnomAD (0.23) and ExAC (0.23) databases [32].

The proportion of CLF in HCV cirrhotic patients grouped according to their PNPLA3 rs738409 genotypes is shown in Fig 1B.

Risk factors for the need of liver transplantation

In multivariate logistic regression analysis, age and PNPLA3 rs738409 genotype turned out to be significant determinants of the need of LT. Specifically, presence of the PNPLA3 G allele increased the risk of LT in CLF 2.4-fold (Fig 2). Other investigated variables such as gender, BMI and type 2 diabetes mellitus did not influence the risk of LT.
Discussion

The study was prompted by our long-term observation that the liver transplant candidates with HCV genotype 1b decompensated liver cirrhosis (or CLF) had significantly more advanced liver dysfunction and were younger than liver transplant candidates with a small HCC. A similar difference in the degree of liver dysfunction between liver transplant candidates indicated for HCV with or without HCC was reported by others [33–35]. However, the age difference between liver transplant candidates was not significant probably due to the fact

![Fig 2. Risk factors for the need of liver transplantation: Multivariate analysis. Bars represent OR with 95% confidence interval.](https://doi.org/10.1371/journal.pone.0222609.g002)
that the patients enrolled in these studies were infected with all HCV genotypes and HCV genotype may modify the risk of HCC [36].

To explain the age difference in our cohort, we assumed that the clinical difference between HCV liver transplant candidates with or without HCC might be caused by some genetic factor. A single nucleotide polymorphism \( PNPLA3 \) rs738409 c.444C>G was identified as a risk factor for concurrent liver steatosis and a faster liver fibrosis progression in patients with chronic HCV infection in the past, but its impact on the need and timing of LT has not been evaluated. In our study, we identified further consequences of the carriage of the G allele: accelerated CLF development requiring LT at a younger age and lower pretransplant blood viral load. The CLF patients were younger than HCC patients and had a significantly higher frequency of \( PNPLA3 \) allele G in comparison with HCC patients as well as with population controls.

The earlier need for LT suggests that the G allele carriage is a strong factor contributing to liver fibrosis progression. Consistently with our results, the recently published studies also presented the G allele carriage as a factor accelerating liver fibrosis progression in patients infected with chronic HCV infection. The meta-analysis by Fan and colleagues [12] showed that Caucasians with chronic HCV infection carrying the GG genotype have a more pronounced liver fibrosis and steatosis. In line with these findings, association of the GG and CG genotypes with progression of liver fibrosis was also demonstrated in a large cohort of HCV-infected patients in the HALT-C study [13].

In contrast to studies documenting association of the \( PNPLA3 \) rs738409 genotype with the risk of HCC development in alcoholic liver disease and non-alcoholic fatty liver disease [21–23], no such association was found in HCV-infected subjects [13, 25]. This led us to initial misinterpretation of our data that the \( PNPLA3 \) G allele was protective from HCC. However, since the G allele carriers underwent liver transplant for CLF at younger age, we realized that they were not able to develop HCC later in the course of the disease. Indeed, age is a well-known risk factor of HCC in patients with chronic HCV infection [37, 38].

As mentioned above, \( PNPLA3 \) G allele carriers with chronic HCV infection have also more pronounced liver steatosis. We assume that in these subjects, lipid accumulation in hepatocytes with subsequent steatohepatitis accelerates progression of liver fibrosis caused by the underlying liver disease which is chronic HCV infection. Indeed, coincidence of chronic HCV infection with lipid accumulation and steatohepatitis results in more rapid development of CLF in comparison with HCV-infected individuals without steatohepatitis [12–16]. The hypothesis of two independent synergic processes leading to CLF (HCV infection and steatohepatitis) is further supported by Jimenez-Sousa et al. [15] who demonstrated a dose dependent effect of \( PNPLA3 \) G allele on the progression of liver stiffness in HCV infected individuals. Finally, a dose dependent effect of \( PNPLA3 \) G allele on the serum ALT activity has recently been described in a large study which included patients with chronic liver disease of various aetiologies [39]. When looking at our data, we realized that there is also a notable dose dependent effect of G allele in our cohort: the proportion of patients transplanted for CLF in the subgroups according to \( PNPLA3 \) genotype increased with the number of G alleles (Fig 1B).

A relatively low number of subjects in the HCC group may be considered as the major disadvantage of our study. On the other hand, the comparison with a large number of population controls confirmed the same G allele frequency in the HCC group and population controls.

We also found that G allele carriers had a lower blood HCV viral load. This has been already known but it seems that the impact of the G allele on viral load is different in different HCV genotypes. Rembek et al. [40] reported a significantly lower viral load in GG homozygotes than in CG and CC genotype carriers infected with HCV genotype 2; however, the \( PNPLA3 \) genotype had no impact on the viral load in subjects infected with HCV genotype 3. Contrarily, Eslam et al. [41] found no impact of the \( PNPLA3 \) genotype on the viral load in a large
study group, but the authors included subjects with various HCV genotypes (1–4) and they did not evaluate subjects with different genotypes separately. Our study group was homogeneous regarding HCV genotypes: all patients were infected with genotype 1b and this fact allowed us to observe the impact of PNPLA3 gene variants on the blood viral load. The HCV replication, virus assembly and release is linked to the host cell lipid metabolism. Endoplasmic reticulum–derived membranous web represents the viral RNA replication complex site and lipid droplets serve as virion assembly sites [42, 43]. It has recently been reported that HCV induces complex remodeling of the host cell lipid metabolism in order to enhance both virus replication and virions assembly [44]. The mechanism by which the PNPLA3 variant protein alters lipid turnover in hepatocytes has also been elucidated: the variant protein accumulates on the surface of lipid droplets [45] and binds the cofactor CGI-58 of adipose triglyceride lipase (ATGL or PNPLA2) [46]. Both inactivated ATGL and the barrier of PNPLA3 variant protein on the surface of lipid droplets impede lipolysis of triglycerides and their trafficking in hepatocytes. We assume that changes in lipid metabolism in hepatocytes caused by the PNPLA3 variant protein may affect the HCV life cycle. We consider the lower blood viral load in G allele carriers as a manifestation of the altered lipid trafficking in hepatocytes, but its impact on liver fibrosis progression remains unclear since long-term lowering of viral load by administration of low doses of interferon alpha had no beneficial effect on liver fibrosis progression in the HALT-C study [47].

Conclusions
In conclusion, our results show that the pronounced liver steatosis and fibrosis in PNPLA3 rs738409 G allele carriers with HCV genotype 1b cirrhosis may have a real impact on the timing and need of liver transplantation. The clinical consequence of G allele carriage could be a faster CLF development and need for liver transplantation at a younger age.

Supporting information
S1 Table. Patients’ clinical and laboratory data.
(XLSX)

Acknowledgments
Thanks to Lucie Budisova for her excellent technical assistance.

Author Contributions
Conceptualization: Renata Senkerikova, Sona Frankova, Milan Jirsa.
Data curation: Milan Jirsa, Dusan Merta.
Formal analysis: Renata Senkerikova, Sona Frankova, Milan Jirsa, Dusan Merta.
Funding acquisition: Milan Jirsa.
Investigation: Renata Senkerikova, Sona Frankova, Milan Jirsa, Miluse Kreidlova.
Methodology: Milan Jirsa, Miluse Kreidlova, Dusan Merta, Magdalena Neroldova, Jan Sperl.
Project administration: Jan Sperl.
Software: Dusan Merta.
Supervision: Milan Jirsa, Julius Spicak, Jan Sperl.
Validation: Jan Sperl.

Writing – original draft: Renata Senkerikova, Sona Frankova, Dusan Merta, Klara Chmelova.

Writing – review & editing: Sona Frankova, Milan Jirsa, Miluse Kreidlova, Julius Spicak, Jan Sperl.

References

1. European Association for the Study of the Liver. Electronic address eee. EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol. 2016; 64(2):433–85. https://doi.org/10.1016/j.jhep.2015.10.006 PMID: 26597456.

2. Singal AG, Manjunath H, Yopp AC, Beg MS, Marrero JA, Gopal P, et al. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. Am J Gastroenterol. 2014; 109(3):325–34. https://doi.org/10.1038/ajg.2013.476 PMID: 24445574.

3. Romeo S, Kozlitina J, Xing C, Pertsemidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008; 40(12):1461–5. https://doi.org/10.1038/ng.257 PMID: 18820647.

4. Kozlitina J, Smagris E, Stender S, Nordestgaard BG, Zhou HH, Tybjærg-Hansen A, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2014; 46(4):352–6. https://doi.org/10.1038/ng.2901 PMID: 24531328.

5. Salameh H, Raff E, Erwin A, Seth D, Nischalke HD, Falletti E, et al. PNPLA3 Gene Polymorphism Is Associated With Predisposition to and Severity of Alcoholic Liver Disease. Am J Gastroenterol. 2015; 110(6):846–56. https://doi.org/10.1038/ajg.2015.137 PMID: 25964223.

6. Speliotes EK, Butler JL, Palmer CD, Voight BF, Consortium G, Consortium MI, et al. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology. 2010; 52(3):904–12. https://doi.org/10.1002/hep.23768 PMID: 20373368.

7. Stickel F, Hampe J, Trepo E, Datz C, Romeo S. PNPLA3 genetic variation in alcoholic steatosis and liver disease progression. Hepatobiliary Surg Nutr. 2015; 4(3):152–60. https://doi.org/10.3978/j.issn.2304-3881.2014.11.04 PMID: 26151055.

8. Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, Dongiovanni P, et al. Homozygosity for the patatin-like phospholipase domain containing 3 gene (PNPLA3) polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2010; 51(4):1209–17. https://doi.org/10.1002/hep.23622 PMID: 20373368.

9. Vespasiani-Gentilucci U, Gallo P, Porcari A, Carotti S, Galati G, Piccioni L, et al. The PNPLA3 rs738409 C > G polymorphism is associated with the risk of progression to cirrhosis in NAFLD patients. Scand J Gastroenterol. 2016; 51(8):967–73. https://doi.org/10.3109/00365521.2016.1161066 PMID: 27150500.

10. Xu R, Tao A, Zhang S, Deng Y, Chen G. Association between patatin-like phospholipase domain containing 3 gene (PNPLA3) polymorphisms and nonalcoholic fatty liver disease: a HuGE review and meta-analysis. Sci Rep. 2015; 5:9284. https://doi.org/10.1038/srep09284 PMID: 25791171.

11. Shen JH, Li YL, Li D, Wang NN, Jing L, Huang YH. The rs738409 (I148M) variant of the PNPLA3 gene and cirrhosis: a meta-analysis. J Lipid Res. 2015; 56(1):167–75. https://doi.org/10.1194/jlr.M048777 PMID: 25378656.

12. Fan JH, Xiang MQ, Li QL, Shi HT, Guo JJ. PNPLA3 rs738409 Polymorphism Associated with Hepatic Steatosis and Advanced Fibrosis in Patients with Chronic Hepatitis C Virus: A Meta-Analysis. Gut Liver. 2016; 10(3):456–63. https://doi.org/10.5009/glt15261 PMID: 26419236.

13. Ali M, Yopp A, Gopal P, Beg MS, Zhu H, Lee W, et al. A Variant in PNPLA3 Associated With Fibrosis Progression but not Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection. Clin Gastroenterol Hepatol. 2016; 14(2):295–300. https://doi.org/10.1016/j.cgh.2015.08.018 PMID: 26305067.

14. Huang CF, Dai CY, Yeh ML, Huang CI, Tai CM, Hsieh MH, et al. Association of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic hepatitis C virus infection. J Hepatol. 2015; 62(3):512–8. https://doi.org/10.1016/j.jhep.2014.10.011 PMID: 25457210.

15. Jimenez-Sousa MA, Gomez-Moreno AZ, Pineda-Tenor D, Sanchez-Ruano JJ, Fernandez-Rodriguez A, Artaza-Varasa T, et al. PNPLA3 rs738409 polymorphism is associated with liver fibrosis progression in patients with chronic hepatitis C: A repeated measures study. J Clin Virol. 2018; 103:71–4. https://doi.org/10.1016/j.jcv.2018.04.008 PMID: 29674183.

16. Manchiero C, Nunes A, Magri MC, Dantas BP, Mazza CC, Barone AA, et al. The rs738409 polymorphism of the PNPLA3 gene is associated with hepatic steatosis and fibrosis in Brazilian patients with chronic hepatitis C. BMC Infect Dis. 2017; 17(1):780. https://doi.org/10.1186/s12879-017-2887-6 PMID: 29258449.
17. Nunez-Torres R, Macias J, Mancebo M, Frias M, Dolci G, Tellez F, et al. The PNPLA3 Genetic Variant rs738409 Influences the Progression to Cirrhosis in HIV/Hepatitis C Virus Coinfected Patients. PLoS One. 2016; 11(12):e0168265. https://doi.org/10.1371/journal.pone.0168265. PMID: 27973562.

18. Sagnelli C, Merli M, Uberti-Foppa C, Hasson H, Cirillo G, Grandone A, et al. Impact of PNPLA3 variants on liver histology of 168 patients with HIV infection and chronic hepatitis C. Clin Microbiol Infect. 2016; 22(4):372–8. https://doi.org/10.1016/j.cmi.2015.11.025. PMID: 26860136.

19. Scheiner B, Mandorfer M, Schwabl P, Payer BA, Bucsis T, Bota S, et al. The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection. PLoS One. 2015; 10(11):e0143429. https://doi.org/10.1371/journal.pone.0143429. PMID: 26590800.

20. Sherman KE, Rouster SD, Kang M, Umbreja T, Sterling R, Butt AA, et al. PNPLA3 Gene Polymorphisms in HCV/HIV-Infected Individuals. Dig Dis Sci. 2018. Epub 2018/09/16. https://doi.org/10.1007/s10620-018-5278-y. PMID: 30218427.

21. Falleti E, Fabris C, Cmet S, Cussigh A, Bitetto D, Fontanini E, et al. PNPLA3 rs738409 C>G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence. Liver Int. 2011; 31(8):1137–43. https://doi.org/10.1111/j.1478-3231.2011.02534.x. PMID: 21745286.

22. Liu YL, Patman GL, Leathart JB, Piguet AC, Burt AD, Dufour JF, et al. Carriage of the PNPLA3 rs738409 C>G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol. 2014; 61(1):75–81. https://doi.org/10.1016/j.jhep.2014.02.030. PMID: 24607626.

23. Trepo E, Guyot E, Ganne-Carrie N, Degre D, Gustot T, Franchimont D, et al. PNPLA3 rs738409 C>G is a common risk variant associated with hepatocellular carcinoma in alcoholic cirrhosis. Hepatology. 2012; 55(4):1307–8. https://doi.org/10.1002/hep.25518. PMID: 22162034.

24. Trepo E, Nahon P, Bontempi G, Valent L, Falleti E, Nischalke HD, et al. Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data. Hepatology. 2014; 59(6):2170–7. https://doi.org/10.1002/hep.26767. PMID: 24114809.

25. Yang J, Trepo E, Nahon P, Cao Q, Moreno C, Letouze E, et al. PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases. Int J Cancer. 2019; 144(3):533–44. https://doi.org/10.1002/ijc.31910. PMID: 30289882.

26. Mazzaferraro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334(11):693–9. https://doi.org/10.1056/NEJM199603143341104. PMID: 8594428.

27. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology; 2001; 33(6):1394–403. https://doi.org/10.1053/hep.2001.24563. PMID: 11391528.

28. Mazzaferraro V, Llovet JM, Miceli R, Bhoori S, Chiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009; 10(1):35–43. https://doi.org/10.1016/S1470-2045(08)70284-5. PMID: 19058754.

29. Cifkova R, Skodova Z, Bruthans J, Adamkova V, Galovcova M, et al. Longitudinal trends in major cardiovascular risk factors in the Czech population between 1985 and 2007/8. Czech MONICA and Czech post-MONICA. Atherosclerosis. 2010; 211(2):676–81. https://doi.org/10.1016/j.atherosclerosis.2010.04.007. PMID: 20471016.

30. Truneczka P, Mikova I, Diouha D, Hubacek JA, Honsova E, Kolesar L, et al. Donor PNPLA3 rs738409 genotype is a risk factor for graft steatosis. A post-transplant biopsy-based study. Dig Liver Dis. 2018; 50(5):490–5. https://doi.org/10.1016/j.dld.2017.12.030. PMID: 29396131.

31. Clarke GM, Anderson CA, Pettersson FH, Cardon LR, Morris AP, Zondervan KT. Basic statistical analysis in genetic case-control studies. Nat Protoc. 2011; 6(2):121–33. https://doi.org/10.1038/nprot.2010.182. PMID: 21293453.

32. https://www.ncbi.nlm.nih.gov/snp/rs738409.

33. Beller LS, Perricone G, Adam R, Cortesi PA, Strazzabosco M, Facchetti R, et al. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. J Hepatol. 2018; 69(4):810–7. https://doi.org/10.1016/j.jhep.2018.06.010. PMID: 29940268.

34. Ferrarese A, Germani G, Gambato M, Russo FP, Senzolo M, Zanetto A, et al. Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study. World J Gastroenterol. 2018; 24(38):4403–11. https://doi.org/10.3748/wjg.v24.i38.4403. PMID: 30344424.
35. Pascasio JM, Vinaixa C, Ferrer MT, Colmenero J, Rubin A, Castells L, et al. Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. J Hepatol. 2017; 67(6):1168–76. https://doi.org/10.1016/j.jhep.2017.08.008 PMID: 28842296.

36. Nkontchou G, Ziol M, Aout M, Labadie M, Baaziz Y, Mahmoudi A, et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. Journal of viral hepatitits. 2011; 18(10):e516–22. Epub 2011/09/15. https://doi.org/10.1111/j.1365-2893.2011.01441.x PMID: 21914071.

37. van der Meer AJ, Feld JJ, Hofer H, Almasio PL, Calvaruso V, Fernandez-Rodriguez CM, et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol. 2017; 66(3):485–93. https://doi.org/10.1016/j.jhep.2016.10.017 PMID: 27780714.

38. Alemán S, Rahbin N, Weiland O, Davidsdottir L, Hedenstierna M, Rose N, et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis. 2013; 57(2):230–6. https://doi.org/10.1093/cid/cit234 PMID: 23616492.

39. Abul-Husn NS, Cheng X, Li AH, Xin Y, Schurmann C, Stevis P, et al. A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease. N Engl J Med. 2018; 378(12):1096–106. https://doi.org/10.1056/NEJMoa1712191 PMID: 29562163.

40. Rembeck K, Maglio C, Lagging M, Christensen PB, Farkkila M, Langeland N, et al. PNPLA3 31148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection. BMC Med Genet. 2012; 13:82. https://doi.org/10.1186/1471-2350-13-82 PMID: 22978414.

41. Eslam M, Mangia A, Berg T, Chan HL, Irving WL, Dore GJ, et al. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. Hepatology. 2016; 64(1):34–46. https://doi.org/10.1002/hep.28475 PMID: 26822232.

42. Aizaki H, Lee KJ, Sung VM, Ishiko H, Lai MM. Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts. Virology. 2004; 324(2):450–61. https://doi.org/10.1006/viro.2004.0303 PMID: 15207630.

43. Merz A, Long G, Hiet MS, Brugger B, Chianda P, Andre P, et al. Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J Biol Chem. 2011; 286(4):3018–32. https://doi.org/10.1074/jbc.M110.175018 PMID: 21056986.

44. Hofmann S, Krajewski M, Scherer C, Scholz V, Mordhorst V, Truschow P, et al. Complex lipid metabolic remodeling is required for efficient hepatitis C virus replication. Biochim Biophys Acta Mol Cell Biol Lipids. 2018; 1863(9):1041–56. https://doi.org/10.1016/j.bbalip.2018.06.002 PMID: 29885363.

45. BasuRay S, Wang Y, Smagris E, Cohen JC, Hobbs HH. Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis. Proc Natl Acad Sci U S A. 2019; 116(19):9521–6. https://doi.org/10.1073/pnas.1901974116 PMID: 31019090.

46. Wang Y, Kory N, BasuRay S, Cohen JC, Hobbs HH. PNPLA3, CGI-58, and Inhibition of Hepatic Triglyceride Hydrolysis in Mice. Hepatology. 2019; 69(6):2427–41. https://doi.org/10.1002/hep.30583 PMID: 30802989.

47. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008; 359(23):2429–41. https://doi.org/10.1056/NEJMoa0707615 PMID: 19052125.